Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | UGCG | Q16739 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248248 | 1.00 | GHSR (0.51) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5248259 | 1.00 | GHSR (0.51) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL6694179 | 0.82 | GHSR (0.48) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5226453 | 0.81 | GHSR (0.49) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5248481 | 0.81 | GHSR (0.79) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5253549 | 0.81 | GHSR (0.79) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5248471 | 0.81 | GHSR (0.79) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5250512 | 0.81 | GHSR (0.59) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5250518 | 0.81 | GHSR (0.59) | GHSRPPARACTSSPPARGKLK7 | |
| SCHEMBL5250516 | 0.81 | GHSR (0.59) | GHSRPPARACTSSPPARGKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869968-B1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6867202-B1 | Increasing level of endogenous growth hormone using growth hormone secretagogue such as 2-amino-N-(2-(3a-benzyl-2-methy-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-(4,3 -c)pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl)-isobutyramide tartarate salt | PFIZER INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6630487-B2 | Treatment of insulin resistance with growth hormone secretagogues | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6482825-B2 | HEXAHYDRO-PYRAZOLO-(4,3-C)PYRIDINE DERIVATIVES USEFUL FOR INCREASING THE ENDOGENOUS PRODUCTION OR RELEASE OF GROWTH HORMONE IN A HUMAN OR OTHER ANIMAL, THUS TREAT OR PREVENT OSTEOPOROSIS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6313140-B1 | ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6110932-A | INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | GHSR 2/4885PPARA 725/4885CTSS 4181/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | GHSR 1/4885PPARA 2011/4885CTSS 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.